These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 20173664)

  • 1. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma.
    Pópulo H; Soares P; Rocha AS; Silva P; Lopes JM
    Melanoma Res; 2010 Apr; 20(2):107-17. PubMed ID: 20173664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
    Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
    Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
    Pantuck AJ; Seligson DB; Klatte T; Yu H; Leppert JT; Moore L; O'Toole T; Gibbons J; Belldegrun AS; Figlin RA
    Cancer; 2007 Jun; 109(11):2257-67. PubMed ID: 17440983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder.
    Sun CH; Chang YH; Pan CC
    Histopathology; 2011 Jun; 58(7):1054-63. PubMed ID: 21707707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung.
    Amin RM; Hiroshima K; Miyagi Y; Kokubo T; Hoshi K; Fujisawa T; Nakatani Y
    Pathol Int; 2008 Jan; 58(1):38-44. PubMed ID: 18067639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases.
    Chaux A; Munari E; Cubilla AL; Hicks J; Lecksell K; Burnett AL; Netto GJ
    Histopathology; 2014 May; 64(6):863-71. PubMed ID: 24279699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
    Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
    BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron deficiency down-regulates the Akt/TSC1-TSC2/mammalian Target of Rapamycin signaling pathway in rats and in COS-1 cells.
    Ndong M; Kazami M; Suzuki T; Uehara M; Katsumata S; Inoue H; Kobayashi K; Tadokoro T; Suzuki K; Yamamoto Y
    Nutr Res; 2009 Sep; 29(9):640-7. PubMed ID: 19854379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
    Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
    J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
    Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
    Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism.
    Sánchez-Hernández I; Baquero P; Calleros L; Chiloeches A
    Cancer Lett; 2012 Jan; 314(2):244-55. PubMed ID: 22056813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphatidylinositol 3' kinase-Akt-mammalian target of rapamycin pathway in smooth muscle tumors of the uterus: selected protein expression patterns and their clinicopathologic implications.
    Fadare O; Renshaw I; Olson SJ; Liang SX
    Int J Gynecol Pathol; 2011 May; 30(3):244-51. PubMed ID: 21464729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
    Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
    BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
    Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
    Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.